Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jan-Dec;13(1):1994834.
doi: 10.1080/19490976.2021.1994834.

Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center

Gianluca Ianiro  1 , Stefano Bibbò  1 , Serena Porcari  1 , Carlo Romano Settanni  1 , Federica Giambò  1 , Andreea Roxana Curta  1 , Gianluca Quaranta  2 , Franco Scaldaferri  1 , Luca Masucci  2 , Maurizio Sanguinetti  2 , Antonio Gasbarrini  1 , Giovanni Cammarota  1
Affiliations
Clinical Trial

Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center

Gianluca Ianiro et al. Gut Microbes. 2021 Jan-Dec.

Abstract

Inflammatory bowel disease (IBD) is a risk factor for C. difficile infection (CDI), which, in turn, complicates the clinical course of IBD. Fecal microbiota transplantation (FMT) is safe and effective in patients with IBD and recurrent CDI (rCDI). In our study, patients with IBD and rCDI received FMT by colonoscopy and were followed-up for 8 weeks. The primary outcome was negative C. difficile toxin 8 weeks after FMT. Eighteen patients with IBD were enrolled. Eight patients received sequential FMT either for pseudomembranous colitis or failure of single fecal infusion. At 8-week follow-up the C. difficile toxin was negative in 17 patients, and most (83%) experienced also improvement of IBD disease activity. Overall, we did not observe any serious adverse event.FMT appears to be highly effective and safe in patients with IBD and rCDI and is likely not only to eradicate CDI but also to improve disease activity of IBD.

Keywords: Clostridioides difficile infection; Crohn’s disease; Fecal microbiota transplantation; gut microbiota; inflammatory bowel disease; microbiome; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

AG reports personal fees for consultancy for Eisai S.r.l., 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, Sinergie S.r.l. Board MRGE, and SanofiS.p.A, personal fees for acting as a speaker for Takeda S.p.A, AbbVie, and Sandoz S.p.A, and personal fees for acting on advisory boards for VSL3 and Eisai. FS has received personal fees for acting as advisor for

Abbvie, Janssen, MSD, Sanofi and Takeda. GC has received personal fees for acting as advisor for Ferring Therapeutics. GI has received personal fees for acting as speaker for Biocodex, Danone, Metagenics, and for acting as consultant/advisor for Ferring Therapeutics, Giuliani, Metagenics. None of other authors has any competing interest to disclose.

Figures

Figure 1.
Figure 1.
Disease activity indexes before and after FMT in our cohort
See this image and copyright information in PMC

References

    1. Dubberke ER, Olsen MA.. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(suppl_2):S88–7. doi:10.1093/cid/cis335. PMID: 22752870; PMCID: PMC3388018. - DOI - PMC - PubMed
    1. Ma GK, Brensinger CM, Wu Q, Lewis JD. Increasing incidence of multiply recurrent Clostridium difficile Infection in the United States. Ann Intern Med. 2017;167(3):152–158. doi:10.7326/M16-2733. Epub 2017 Jul 4. PMID: 28672282. - DOI - PubMed
    1. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8(1):17–26. doi:10.1038/nrgastro.2010.190. PMID: 21119612. - DOI - PubMed
    1. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443–1450. doi:10.1111/j.1572-0241.2007.01780.x. PMID: 18513271. - DOI - PubMed
    1. Razik R, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol. 2016;111:1141–1146. doi:10.1038/ajg.2016.187. PMID: 27215924. - DOI - PubMed

Publication types

LinkOut - more resources